Catalog No.
Product Name
Application
Product Information
Citations
-
HSD17B13 Inhibitor
HSD17B13-IN-39 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), a key enzyme implicated in lipid metabolism and liver function. This compound is particularly relevant for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. HSD17B13-IN-39 provides essential insights into the role of HSD17B13 in disease mechanisms and potential therapeutic interventions. -
17β-HSD Inhibitor
HSD17B13-IN-1 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM with estradiol as a substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). HSD17B13-IN-1 provides valuable insights into the biochemical pathways involved in fatty liver disease and serves as a potential therapeutic target for related conditions. -
17β-HSD Inhibitor
HSD17B13-IN-31 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound is crucial in researching nonalcoholic fatty liver diseases (NAFLDs), particularly nonalcoholic steatohepatitis (NASH), by modulating lipid metabolism and inflammation. HSD17B13-IN-31 serves as a valuable tool for studying the role of HSD17B13 in liver-related disorders and therapeutic interventions. -
AKR1C3 Inhibitor
CRT0083914 is a selective non-carboxylate inhibitor of the enzyme AKR1C3. This compound exhibits significant biological activity against AKR1C3, making it a valuable tool for studying its role in colon cancer. Researchers can utilize CRT0083914 to explore its potential therapeutic effects and mechanistic insights in the context of cancer research. -
17β-HSD Inhibitor
HSD17B13-IN-42 targets hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) as a potent inhibitor, exhibiting an IC50 of less than 0.1 μM with estradiol substrates. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), making it a valuable tool for researchers investigating metabolic disorders and liver pathologies. -
HSD17B13 Inhbitor
HSD17B13-IN-37 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound is utilized in research focused on nonalcoholic fatty liver disease (NAFLD), where it aids in elucidating the role of HSD17B13 in lipid metabolism and liver pathophysiology. Its potent inhibitory activity makes it a valuable tool for investigating therapeutic strategies targeting HSD17B13-related pathways. -
HSD17B13 Inhibitor
HSD17B13-IN-102 is a potent inhibitor of the enzyme hydroxysteroid dehydrogenase 17 beta 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM with estradiol. This compound is instrumental in research focused on steroid metabolism and associated diseases, particularly in the context of liver function and metabolic disorders. Its selective inhibition provides a valuable tool for investigating the biological roles of HSD17B13 in various physiological and pathological conditions. -
17β-HSD Inhibitor
HSD17B13-IN-16 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound has significant relevance in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). HSD17B13-IN-16 serves as a valuable tool for researchers investigating metabolic disorders and potential therapeutic interventions in liver diseases. -
17β-HSD Inhibitor
HSD17B13-IN-35 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM when estradiol is used as a substrate. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), by targeting metabolic pathways involved in lipid metabolism. Its effective inhibition of HSD17B13 makes it a valuable reagent for research into therapeutic strategies for liver-related disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-63 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research applications related to liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its efficacy in modulating HSD17B13 activity provides insights into the underlying mechanisms of these diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-57 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is relevant for investigations into liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). HSD17B13-IN-57 serves as a valuable tool for studying the biochemical pathways involved in these diseases. -
17β-HSD Inhibitor
HSD17B13-IN-28 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol as substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its ability to modulate HSD17B13 activity makes it a valuable tool for exploring the metabolic mechanisms underpinning liver disorders and evaluating potential therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-100 is a potent inhibitor of HSD17B13, exhibiting an IC50 value of less than 0.1 μM in the presence of estradiol. This compound is essential for researchers investigating the role of HSD17B13 in steroid metabolism and related pathways. Its selective inhibition can facilitate studies on various conditions associated with altered steroidogenesis, including liver diseases and metabolic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-80 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound plays a crucial role in research focusing on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibitory activity makes it a valuable tool for investigating the pathophysiological mechanisms underlying these diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-44 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for investigating its role in liver diseases and metabolic disorders, providing insights into the biochemical pathways associated with these conditions. Researchers can utilize HSD17B13-IN-44 to explore therapeutic targets and validate the significance of HSD17B13 in various biological processes. -
HSD17B13 Inhibitor
HSD17B13-IN-45 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is instrumental in exploring pathways associated with liver diseases and metabolic disorders. Researchers can utilize HSD17B13-IN-45 to investigate the role of HSD17B13 in various biological contexts and its potential as a therapeutic target. -
HSD17B13 Inhibitor
HSD17B13-IN-81 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is utilized in research focused on liver diseases, metabolic disorders, and cardiovascular diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, it serves as a valuable tool in studies related to drug-induced liver injury (DILI). -
17β-HSD Inhibitor
HSD17B13-IN-40 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 of less than 0.1 μM against estradiol substrates. This compound is significant for research related to nonalcoholic fatty liver diseases (NAFLD), particularly nonalcoholic steatohepatitis (NASH), as it may provide insights into the modulation of lipid metabolism and inflammatory pathways. The compound's inhibitory action on HSD17B13 highlights its potential utility in exploring therapeutic strategies for metabolic disorders. -
HSD17B13 Inhbitor
HSD17B13-IN-58 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in the research of nonalcoholic fatty liver diseases (NAFLD), contributing to the understanding of lipid metabolism and hormonal regulation in hepatic disorders. Its selective inhibition offers valuable insights into therapeutic strategies targeting HSD17B13 in liver-related diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-33 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound plays a crucial role in research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective activity makes it a valuable tool for investigating the therapeutic potential in these diseases. -
17β-HSD Inhibitor
HSD17B13-IN-30 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol substrates. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), due to its role in modulating steroid metabolism and fatty liver progression. HSD17B13-IN-30 facilitates research into therapeutic approaches for liver-related metabolic disorders. -
17β-HSD1 Inhibitor
17β-HSD1-IN-2 is a non-estrogenic, steroidal covalent irreversible inhibitor of 17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1), exhibiting a Ki of 368 nM. This compound demonstrates potential for studying estrogen-dependent disorders, facilitating research into therapeutic strategies for conditions influenced by estrogen metabolism. Its selective inhibition of 17β-HSD1 offers valuable insights into the enzyme's role in various biological processes and disease states. -
HSD17B13 Inhibitor
HSD17B13-IN-14 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. This compound is valuable for research into hepatic conditions, metabolic diseases, and cardiovascular disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibition of HSD17B13 makes it an important tool for studying the underlying mechanisms of these diseases. -
HSD17B13 synthesis reducer
Gatuzosiran is a small interfering RNA (siRNA) that targets and reduces the synthesis of 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13). This compound plays a crucial role in research focused on fatty liver disease, providing insights into the molecular mechanisms underlying lipid metabolism and liver function. Its ability to modulate HSD17B13 expression makes it a valuable tool for studying the pathophysiology of liver diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-53 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver-related pathologies, metabolic disorders, and cardiovascular diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as studies on drug-induced liver injury (DILI). -
HSD17B13 Inhibitor
HSD17B13-IN-47 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for studying the role of HSD17B13 in liver diseases and metabolic disorders, facilitating research into therapeutic interventions targeting these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-83 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is relevant for investigations into liver and metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its specificity and efficacy make it a valuable tool for advancing research in the fields of hepatology and cardiovascular health. -
HSD17B13 Inhbitor
HSD17B13-IN-62-d3 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), facilitating the investigation of HSD17B13's role in lipid metabolism and liver function. Its selective inhibition provides valuable insights into the therapeutic potential for addressing metabolic liver disorders. -
HSD17B13 Inhbitor
HSD17B13-IN-34 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily deployed in research related to nonalcoholic fatty liver disease (NAFLD), facilitating the investigation of HSD17B13's role in lipid metabolism and liver function. Its selective inhibition offers valuable insights into therapeutic strategies targeting dysregulated steroid metabolism in hepatic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-56 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is crucial for investigating the role of HSD17B13 in various hepatic and metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibition makes it a valuable tool for advancing research in liver pathology and associated cardiovascular conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-51 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as drug-induced liver injury (DILI). Its specific targeting of HSD17B13 positions it as a critical tool for investigating metabolic and cardiovascular disease pathways. -
17BHSD13 Inhibitor
HSD17B13-IN-105 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase 13 (17BHSD13), exhibiting an IC50 value of 0.036 μM and notable selectivity against 17BHSD4 with an IC50 of 31.5 μM. This compound is valuable for research applications targeting liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its specificity and potent inhibition profile make it a significant tool for studying the biochemical pathways involved in these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-48 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibitory action on HSD17B13 makes it a crucial tool for research into the pathophysiology and therapeutic targeting of these conditions. -
HSD17B13 Inhbitor
HSD17B13-IN-89 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This reagent is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), offering valuable insights into the role of HSD17B13 in hepatic metabolism and disease progression. Its specificity and efficacy make it a critical tool for studying the pathophysiology of metabolic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-82 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as in metabolic and cardiovascular disorders. Additionally, HSD17B13-IN-82 is useful for studying drug-induced liver injury (DILI) and its underlying mechanisms. -
AKR1C3 Inhibitor
Indomethacin methylester is a selective inhibitor of AKR1C3, exhibiting an IC50 of 5.67 μM. This compound is particularly relevant for studying its role in prostate cancer research, where it may aid in elucidating the mechanisms underlying tumor progression and therapeutic resistance. Its specificity for AKR1C3 offers potential insights into targeting this enzyme for cancer treatment strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-71 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research targeting liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, HSD17B13-IN-71 can aid in investigations of drug-induced liver injury (DILI), making it a crucial tool in related biological studies. -
HSD17B13 Inhibitor
HSD17B13-IN-104 is a potent and selective inhibitor of HSD17B13, exhibiting an IC50 of 2.5 nM. This compound effectively modulates hepatic lipid metabolism by targeting the SREBP-1c/FAS signaling pathway, thereby reducing hepatic lipid accumulation. HSD17B13-IN-104 holds potential for advancing research on metabolic dysfunction-associated steatohepatitis and related conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-95 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), with an IC50 value for estradiol of less than 0.1 μM. This compound is useful in the investigation of nonalcoholic fatty liver disease and other metabolic disorders associated with altered steroid hormone metabolism. Its ability to effectively modulate HSD17B13 activity makes it a valuable tool for research into the biological mechanisms underlying liver function and related pathologies. -
HSD17B13 Inhibitor
HSD17B13-IN-72 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for studying the role of HSD17B13 in liver diseases and metabolic disorders, facilitating research into potential therapeutic interventions and mechanisms underlying these conditions. Its high specificity makes it an important tool for elucidating the biological pathways associated with steroid metabolism. -
HSD17B13 Inhbitor
HSD17B13-IN-24 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), facilitating the understanding of metabolic pathways and potential therapeutic targets in liver disorders. Its high specificity makes it a valuable tool for investigating the role of HSD17B13 in various biological contexts. -
HSD17B13 Inhibitor
HSD17B13-IN-55 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. Additionally, it may support research into drug-induced liver injury (DILI), providing insights into its mechanisms and potential therapeutic interventions. -
HSD17B13 Inhibitor
HSD17B13-IN-61 is a specific inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is intended for research into liver-related conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI), as well as various metabolic and cardiovascular diseases. Its high potency makes it a valuable tool for investigating the role of HSD17B13 in these disease contexts. -
HSD17B13 Inhbitor
HSD17B13-IN-90 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenases, specifically targeting HSD17B13, with an IC50 of less than 0.1 μM for estradiol. This compound is employed in research related to nonalcoholic fatty liver disease (NAFLD), providing insights into the role of HSD17B13 in lipid metabolism and liver function. Its potent inhibitory activity makes it a valuable tool for investigating the biological effects of steroid hormone modulation in various pathological contexts. -
17β-HSD Inhibitor
HSD17B13-IN-21 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its application in research could provide insight into the mechanisms underlying liver-related metabolic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-12 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for both leukotriene B3 and estradiol. This compound is valuable for studying liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its targeted inhibition offers insights into the biochemical pathways associated with these health issues. -
HSD17B13 Inhibitor
HSD17B13-IN-54 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in various pathologies, including liver diseases, metabolic disorders, and cardiovascular conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, it serves as a useful tool for studying drug-induced liver injury (DILI). -
PROTAC
PTOTAC HSD17B13 degrader 1 is a PROTAC designed to selectively target and promote the degradation of 17β-Hydroxysteroid dehydrogenase 13 (HSD17B13). This compound consists of a specific ligand for HSD17B13, a linker based on tert-Butyl 5-bromoisoindoline-2-carboxylate, and a ligand for an E3 ubiquitin ligase, enabling effective ubiquitination and subsequent proteasomal degradation of the target protein. PTOTAC HSD17B13 degrader 1 is a valuable tool for studying HSD17B13 functions and has potential applications in therapeutic development and protein regulation research. -
HSD17B13 Inhibitor
HSD17B13-IN-96 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), exhibiting an IC50 value for estradiol of less than 0.1 μM. This compound is primarily utilized in research focused on nonalcoholic fatty liver disease (NAFLD) and related metabolic disorders. Its effectiveness in modulating HSD17B13 activity provides valuable insights into the biological pathways involved in liver metabolism and pathology. -
HSD17B13 Inhbitor
HSD17B13-IN-25 is a specific inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound plays a significant role in the study of nonalcoholic fatty liver disease (NAFLD) by modulating steroid metabolism and fatty liver progression. Its application in preclinical research facilitates a deeper understanding of HSD17B13's involvement in lipid metabolism and liver pathology.
